These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22867717)

  • 1. Outer membrane vesicles (OMV) production of Neisseria meningitidis serogroup B in batch process.
    Santos S; Arauz LJ; Baruque-Ramos J; Lebrun I; Carneiro SM; Barreto SA; Schenkman RP
    Vaccine; 2012 Sep; 30(42):6064-9. PubMed ID: 22867717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media.
    Tsolakos N; Lie K; Bolstad K; Maslen S; Kristiansen PA; Høiby EA; Wallington A; Vipond C; Skehel M; Tang CM; Feavers IM; Wedege E; Wheeler JX
    Vaccine; 2010 Apr; 28(18):3211-8. PubMed ID: 20188677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outer membrane vesicles of the VA-MENGOC-BC vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry.
    Uli L; Castellanos-Serra L; Betancourt L; Domínguez F; Barberá R; Sotolongo F; Guillén G; Pajón Feyt R
    Proteomics; 2006 Jun; 6(11):3389-99. PubMed ID: 16673438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous production of Neisseria meningitidis outer membrane vesicles.
    Gerritzen MJH; Stangowez L; van de Waterbeemd B; Martens DE; Wijffels RH; Stork M
    Appl Microbiol Biotechnol; 2019 Dec; 103(23-24):9401-9410. PubMed ID: 31676919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
    Sanders H; Feavers IM
    Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development.
    van de Waterbeemd B; Zomer G; van den Ijssel J; van Keulen L; Eppink MH; van der Ley P; van der Pol LA
    PLoS One; 2013; 8(1):e54314. PubMed ID: 23372704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
    van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
    Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens.
    Vaughan TE; Skipp PJ; O'Connor CD; Hudson MJ; Vipond R; Elmore MJ; Gorringe AR
    Vaccine; 2006 Jun; 24(25):5277-93. PubMed ID: 16682101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt.
    Norheim G; Tunheim G; Næss LM; Kristiansen PA; Caugant DA; Rosenqvist E
    Scand J Immunol; 2012 Aug; 76(2):99-107. PubMed ID: 22537024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
    Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
    Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dissolved oxygen tension triggers outer membrane vesicle formation by Neisseria meningitidis.
    Gerritzen MJH; Maas RHW; van den Ijssel J; van Keulen L; Martens DE; Wijffels RH; Stork M
    Microb Cell Fact; 2018 Oct; 17(1):157. PubMed ID: 30285743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant.
    Williams JN; Skipp PJ; Humphries HE; Christodoulides M; O'Connor CD; Heckels JE
    Infect Immun; 2007 Mar; 75(3):1364-72. PubMed ID: 17158897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254.
    Vipond C; Suker J; Jones C; Tang C; Feavers IM; Wheeler JX
    Proteomics; 2006 Jun; 6(11):3400-13. PubMed ID: 16645985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.